<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medecol</journal-id><journal-title-group><journal-title xml:lang="ru">Медицина и экология</journal-title><trans-title-group xml:lang="en"><trans-title>Medicine and ecology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-6045</issn><issn pub-type="epub">2305-6053</issn><publisher><publisher-name>Карагандинский медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">medecol-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LITERATURE REVIEWS</subject></subj-group></article-categories><title-group><article-title>ОСОБЕННОСТИ HER-2/NEU ПОЗИТИВНОГО ИММУНОГИСТОХИМИЧЕСКОГО ФЕНОТИПА РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ В РАЗНЫХ ЭТНИЧЕСКИХ ГРУППАХ</article-title><trans-title-group xml:lang="en"><trans-title>ETHNIC FEATURES OF HER2NEW POSITIVE IMMUNOHISTOCHEMICAL PHENOTYPE OF BREAST CANCER</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полуэктова</surname><given-names>Я. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Poluektova</surname><given-names>Ya. L.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кабилдина</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kabildina</surname><given-names>N. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сирота</surname><given-names>В. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Sirota</surname><given-names>V. B.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сапар</surname><given-names>Б. ..</given-names></name><name name-style="western" xml:lang="en"><surname>Sapar</surname><given-names>B. ..</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Карагандинский государственный медицинский университет<country>Казахстан</country></aff><aff xml:lang="en">Karaganda state medical university<country>Kazakhstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>07</day><month>09</month><year>2021</year></pub-date><volume>0</volume><issue>1</issue><fpage>29</fpage><lpage>35</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Полуэктова Я.Л., Кабилдина Н.А., Сирота В.Б., Сапар Б..., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Полуэктова Я.Л., Кабилдина Н.А., Сирота В.Б., Сапар Б...</copyright-holder><copyright-holder xml:lang="en">Poluektova Y.L., Kabildina N.A., Sirota V.B., Sapar B...</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://medecol.qmu.kz/jour/article/view/7">https://medecol.qmu.kz/jour/article/view/7</self-uri><abstract><p>Из десяти миллионов зарегистрированных новых случаев злокачественных заболеваний во всем мире 1012% приходится на рак молочной железы. Согласно проводимым в США исследованиям, заболеваемость раком молочной железы неуклонно растет у женщин старшей возрастной категории, а именно после наступления менопаузы. Эти возрастные показатели заболеваемости выше у белокожих женщин, нежели у темнокожей расы. Хотя в отличие от этих показателей, показатели смертности от рака молочной железы у темнокожих женщин выше. В Казахстане рак молочной железы стоит на первом месте среди онкопатологии у женщин. К сожалению, заболеваемость с каждым годом неуклонно растет. Существуют различия заболеваемости раком молочной железы среди разных этносов, это связывают с традициями и образом жизни различных народов. Вопрос расовых отличий у больных раком молочной железы в последнее время приобретает все более актуальный характер. В эпоху индивидуализации лечения, знание этнических особенностей, таких как агрессивность опухоли, ее иммуногистохимические характеристики у представителей разных национальностей, представляется необходимым и логичным. Проведенный литературный поиск показал, что такие вопросы более или менее хорошо освещены только в Соединенных Штатах Америки. В Европе, Азии, Африке, Южной Америке подобных исследований нет или они носят единичный характер с небольшой выборкой пациентов.</p></abstract><trans-abstract xml:lang="en"><p>Breast cancer is a malignant tumor of the glandular tissue of the breast. According to IARC, 167,114 new cases of breast cancer are registered in the world annually. In the structure of oncological pathology, this localization takes first place for many years. 10-12% of the world's total is breast cancer out of ten million new cases of malignant diseases. According to research in the US, the incidence of breast cancer is steadily increasing in older women, namely after the onset of menopause. These age-specific morbidity rates are higher in Caucasian women than afroamericans. Although the mortality rates from breast cancer in black women are higher. In Kazakhstan breast cancer takes the first place among other cancers in women. Unfortunately, the incidence rate is increasing year by year. There are differences in the incidence of breast cancer among diverse ethnic groups, this is associated with the traditions and way of life of various peoples. The issue of racial differences in patients with breast cancer (BC) has recently become more topical. In the era of individualization of treatment, knowledge of ethnic characteristics, such as tumor aggressiveness, its immunohistochemical characteristics in representatives of different nationalities, seems necessary and logical. A conducted literary search has shown that that question is more covered only in the United States of America (USA). The similar studies are not available or they are of a single character with a small sample of patients in Europe, Asia, Africa, South America.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>этнос</kwd><kwd>раса</kwd><kwd>заболеваемость</kwd><kwd>смертность</kwd><kwd>сүт безінің қатерлі ісігі</kwd><kwd>этнос</kwd><kwd>нәсіл</kwd><kwd>ауырушылық</kwd><kwd>өлім-жітім</kwd></kwd-group><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>ethnos</kwd><kwd>race</kwd><kwd>morbidity</kwd><kwd>mortality</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Заридзе Д. Г. Эпидемиология и скрининг рака молочной железы //Вопросник онкологии. - 2002. - Т. 48, №4-5. - С. 489-495.</mixed-citation><mixed-citation xml:lang="en">Заридзе Д. Г. Эпидемиология и скрининг рака молочной железы //Вопросник онкологии. - 2002. - Т. 48, №4-5. - С. 489-495.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Кулигина Е. Ш. Иммуногистохимия рака молочной железы. - М., 2011. - С. 25-28.</mixed-citation><mixed-citation xml:lang="en">Кулигина Е. Ш. Иммуногистохимия рака молочной железы. - М., 2011. - С. 25-28.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Показатели онкологической службы Республики Казахстан за 2013 год /К. Ш. Нургазиев, Д. М. Байпеисов, Г. Т. Сейсенбаева и др. - Алматы, 2014. - 104 с.</mixed-citation><mixed-citation xml:lang="en">Показатели онкологической службы Республики Казахстан за 2013 год /К. Ш. Нургазиев, Д. М. Байпеисов, Г. Т. Сейсенбаева и др. - Алматы, 2014. - 104 с.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Райхман Я. Национальные традиции образа жизни и риск возникновения рака // www.all-about-cancerprevention.com/nac_1.html</mixed-citation><mixed-citation xml:lang="en">Райхман Я. Национальные традиции образа жизни и риск возникновения рака // www.all-about-cancerprevention.com/nac_1.html</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Шубин В. П. Молекулярно -генетический анализ особенностей структуры и экспрессии генов BRCA1/2 при раке яичников и молочной железы: Автореф. дис..канд. биол. наук. - М., 2011. - С. 18-19.</mixed-citation><mixed-citation xml:lang="en">Шубин В. П. Молекулярно -генетический анализ особенностей структуры и экспрессии генов BRCA1/2 при раке яичников и молочной железы: Автореф. дис..канд. биол. наук. - М., 2011. - С. 18-19.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">An overview of prognostic factors for long-term survivors of breast cancer /I. Soerjomataram, M. W. Louwman, J. G. Ribot et al. //Breast Cancer Res. Treat. - 2008. - V. 107, №3. - P. 309-323.</mixed-citation><mixed-citation xml:lang="en">An overview of prognostic factors for long-term survivors of breast cancer /I. Soerjomataram, M. W. Louwman, J. G. Ribot et al. //Breast Cancer Res. Treat. - 2008. - V. 107, №3. - P. 309-323.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Breast cancer in Nigeria and Finland: epidemiological, clinical and histological comparison /O. F. Ikpatt, T. Kuopio, R. Ndoma-Egba, Y. Collan //Anticancer. Res. - 2002. - V. 22, №5. -Pp. 3005-3012.</mixed-citation><mixed-citation xml:lang="en">Breast cancer in Nigeria and Finland: epidemiological, clinical and histological comparison /O. F. Ikpatt, T. Kuopio, R. Ndoma-Egba, Y. Collan //Anticancer. Res. - 2002. - V. 22, №5. -Pp. 3005-3012.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Breast carcinoma tumor characteristics in black and white women /J. G. Elmore, V. M. Moceri, D. Carter, E. B. Larson //Cancer. - 1998. - V. 83, №12. - P. 2509-2515.</mixed-citation><mixed-citation xml:lang="en">Breast carcinoma tumor characteristics in black and white women /J. G. Elmore, V. M. Moceri, D. Carter, E. B. Larson //Cancer. - 1998. - V. 83, №12. - P. 2509-2515.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Clinicopathologic significance of the basal -like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes /M. J. Kim, J. Y. Ro, S. H. Ahn et al. //Hum. Pathol. - 2006. - V. 37, №9. - Pp. 1217-1226.</mixed-citation><mixed-citation xml:lang="en">Clinicopathologic significance of the basal -like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes /M. J. Kim, J. Y. Ro, S. H. Ahn et al. //Hum. Pathol. - 2006. - V. 37, №9. - Pp. 1217-1226.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study /S. Bianchi, D. Palli, M. Falchetti et al. /J. Cell Physiol. - 2006. - V. 206, №3. - Pp. 702-708.</mixed-citation><mixed-citation xml:lang="en">ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study /S. Bianchi, D. Palli, M. Falchetti et al. /J. Cell Physiol. - 2006. - V. 206, №3. - Pp. 702-708.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Estimates of worldwide burden of cancer in 2008 /J. Ferlay, H. R. Shin, F. Bray, D. Forman et al. //Int. J. Cancer - 2010. - V. 127. - Pp. 2893-2917.</mixed-citation><mixed-citation xml:lang="en">Estimates of worldwide burden of cancer in 2008 /J. Ferlay, H. R. Shin, F. Bray, D. Forman et al. //Int. J. Cancer - 2010. - V. 127. - Pp. 2893-2917.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance /G. Arpino, H. Weiss, A. V. Lee et al. //J. Natl. Cancer Inst. - 2005. - V. 7, №97. - Pp. 1254-1261.</mixed-citation><mixed-citation xml:lang="en">Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance /G. Arpino, H. Weiss, A. V. Lee et al. //J. Natl. Cancer Inst. - 2005. - V. 7, №97. - Pp. 1254-1261.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ethnicity and breast cancer: factors influencing differences in incidence and outcome / R. T. Chlebowski, Z. Chen, G. L. Anderson et al. // J. Natl. Cancer. Inst. - 2005. - V. 97, №6. - P. 439-448.</mixed-citation><mixed-citation xml:lang="en">Ethnicity and breast cancer: factors influencing differences in incidence and outcome / R. T. Chlebowski, Z. Chen, G. L. Anderson et al. // J. Natl. Cancer. Inst. - 2005. - V. 97, №6. - P. 439-448.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Expression of cerbB2 protein and its relation to prognosis in 284 primary breast cancer patients /L. F. Yang, S. T. Song, X. B. Li et al. // Zhonghua Zhong Liu Za Zhi. - 2006. - V. 28, №4. - P. 294-297.</mixed-citation><mixed-citation xml:lang="en">Expression of cerbB2 protein and its relation to prognosis in 284 primary breast cancer patients /L. F. Yang, S. T. Song, X. B. Li et al. // Zhonghua Zhong Liu Za Zhi. - 2006. - V. 28, №4. - P. 294-297.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Fejerman L. Population differences in breast cancer severity /L. Fejerman, E. Ziv // Pharmacogenomics. - 2008. - V. 9, №3. - Pp. 323-333.</mixed-citation><mixed-citation xml:lang="en">Fejerman L. Population differences in breast cancer severity /L. Fejerman, E. Ziv // Pharmacogenomics. - 2008. - V. 9, №3. - Pp. 323-333.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information /L. Ryden, G. Landberg, O. Stal et al. //Breast Cancer Res. Treat. - 2008. - V. 109, №2. - P. 351-357.</mixed-citation><mixed-citation xml:lang="en">HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information /L. Ryden, G. Landberg, O. Stal et al. //Breast Cancer Res. Treat. - 2008. - V. 109, №2. - P. 351-357.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13 239 cases /S. M. Gapstur, J. Dupuis, P. Gann et al. //Cancer. - 1996. -V. 77, №8. - P. 1465-1471.</mixed-citation><mixed-citation xml:lang="en">Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13 239 cases /S. M. Gapstur, J. Dupuis, P. Gann et al. //Cancer. - 1996. -V. 77, №8. - P. 1465-1471.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Jatoi I. Qualitative age interactions in breast cancer studies : a minireview /I. Jatoi, W. F. Anderson //Future Oncol. - 2010. - V. 6. - Pp. 1781-1788.</mixed-citation><mixed-citation xml:lang="en">Jatoi I. Qualitative age interactions in breast cancer studies : a minireview /I. Jatoi, W. F. Anderson //Future Oncol. - 2010. - V. 6. - Pp. 1781-1788.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Joslyn S. A. Hormone receptors in breast cancer: racial differences in distribution and survival //Breast Cancer Res. Treat. - 2002. -V. 73, №1. - P. 45-59.</mixed-citation><mixed-citation xml:lang="en">Joslyn S. A. Hormone receptors in breast cancer: racial differences in distribution and survival //Breast Cancer Res. Treat. - 2002. -V. 73, №1. - P. 45-59.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Li C. I. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older /C. I. Li, K. E. Malone, J. R. Daling //Cancer Epidemiol. Biomarkers Prev. - 2002. - V. 11, №7. - Pp. 601-607.</mixed-citation><mixed-citation xml:lang="en">Li C. I. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older /C. I. Li, K. E. Malone, J. R. Daling //Cancer Epidemiol. Biomarkers Prev. - 2002. - V. 11, №7. - Pp. 601-607.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Li C. I. Differences in breast cancer stage, treatment, and survival by race and ethnicity /C. I. Li, K. E. Malone, J. R. Daling //Arch. Intern. Med. - 2003. - V. 163, №1. - P. 49-56.</mixed-citation><mixed-citation xml:lang="en">Li C. I. Differences in breast cancer stage, treatment, and survival by race and ethnicity /C. I. Li, K. E. Malone, J. R. Daling //Arch. Intern. Med. - 2003. - V. 163, №1. - P. 49-56.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer /M. Martin, A. Rodriguez-Lescure, A. Ruiz et al. // Breast Cancer Res. Treat. - 2010. - V. 123. - Pp. 149-157.</mixed-citation><mixed-citation xml:lang="en">Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer /M. Martin, A. Rodriguez-Lescure, A. Ruiz et al. // Breast Cancer Res. Treat. - 2010. - V. 123. - Pp. 149-157.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Parker J. S. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial //J. Clin. Oncol. - 2009. -V. 27. - Pp. 1168-1176.</mixed-citation><mixed-citation xml:lang="en">Parker J. S. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial //J. Clin. Oncol. - 2009. -V. 27. - Pp. 1168-1176.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu / A. T. Stark, S. Claud, A. Kapke et al. //Cancer. - 2005. - V. 104, №10. - Pp. 2189-2196.</mixed-citation><mixed-citation xml:lang="en">Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu / A. T. Stark, S. Claud, A. Kapke et al. //Cancer. - 2005. - V. 104, №10. - Pp. 2189-2196.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma /P. L. Porter, M. J. Lund, M. G. Lin et al. // Cancer. - 2004. - V. 100. - P. 2533-2542.</mixed-citation><mixed-citation xml:lang="en">Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma /P. L. Porter, M. J. Lund, M. G. Lin et al. // Cancer. - 2004. - V. 100. - P. 2533-2542.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Reis-Filho J. S. Triple negative tumours: a critical review /J. S. Reis-Filho, A. N. J. Tutt // Histopathology. - 2008. - V. 52. - Pp. 108-118.</mixed-citation><mixed-citation xml:lang="en">Reis-Filho J. S. Triple negative tumours: a critical review /J. S. Reis-Filho, A. N. J. Tutt // Histopathology. - 2008. - V. 52. - Pp. 108-118.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">The protective role of pregnancy in breast cancer /J. Russo, R. Moral, G. A. Balogh et al. //Breast Cancer Res. - 2011. - V. 7. - Pp. 131 -142.</mixed-citation><mixed-citation xml:lang="en">The protective role of pregnancy in breast cancer /J. Russo, R. Moral, G. A. Balogh et al. //Breast Cancer Res. - 2011. - V. 7. - Pp. 131 -142.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Trends in breast cancer by race and ethnicity: update 2006 /C. Smigal, A. Jemal, E. Ward et al. //CA Cancer J. Clin. - 2006. - V. 56, №3. - P. 168-183.</mixed-citation><mixed-citation xml:lang="en">Trends in breast cancer by race and ethnicity: update 2006 /C. Smigal, A. Jemal, E. Ward et al. //CA Cancer J. Clin. - 2006. - V. 56, №3. - P. 168-183.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Tumor markers in breast cancer- European Group on Tumor Markers recommendations /R. Molina, V. Barak, A. van Dalen et al. // Tumour Biology. - 2015. - V. 26, №6. - Pp. 281293.</mixed-citation><mixed-citation xml:lang="en">Tumor markers in breast cancer- European Group on Tumor Markers recommendations /R. Molina, V. Barak, A. van Dalen et al. // Tumour Biology. - 2015. - V. 26, №6. - Pp. 281293.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
